Table 3.
Pharmacokinetic Parametersa Week 1 of Tigatuzumab Infusion
| CS-1008 (mg/kg) | Cmax (μg/mL) | Cmin—168 hours (μg/mL) | AUC0–168 (μg/mL · hr) | Tmax (Hours) | T½(Hours) | Cl (mL/hours) | VD (mL) |
|---|---|---|---|---|---|---|---|
| 1 | 29.6 ± 2.7 | 14.0 ± 3.6 | 3140.5 ± 182.9 | 2.4 ± 1.6 | 227.8 ± 5.4 | 11.7 ± 1.0 | 3875.3 ± 1105.9 |
| 2 | 56.7 ± 10.2 | 30.2 ± 9.1 | 6220.9 ± 1072.1 | 6.4 ± 6.0 | 163.5 ± 46.2 | 18.5 ± 5.8 | 4256.9 ± 1521.8 |
| 4 | 110.2 ± 16.4 | 48.8 ± 11.5 | 10753.8 ± 876.9 | 2.2 ± 0.7 | 154.9 ± 25.7 | 14.4 ± 1.2 | 3177.4 ± 3177.4 |
| 8 | 167.0 ± 41.4 | 58.6 ± 23.9 | 16,081.0 ± 4244.9 | 1.8 ± 0.4 | 149.4 ± 38.6 | 20.1 ± 4.7 | 4174.9 ± 741.5 |
a
Pharmacokinetic parameters were calculated by the noncompartmental method, using the WinNonlin version 4.0 program (Pharsight Corp., Mountain View, CA).
Cmax, maximum plasma-serum concentration; Cmin, minimum plasma-serum concentration; AUC, area under the concentration versus time curve; T½, serum half-life; Cl, clearance; VD, volume of distribution.